ArticleBMC pulmonary medicine2026
Inflammatory phenotype drives different immunosuppressive response in COPD exacerbations.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCOPD is heterogeneous, with immunosuppression contributing to immune dysfunction. We hypothesized that the immunosuppressive response varies by inflammatory phenotype during both stable disease (SCOPD) and acute exacerbations (AECOPD).
methodsCOPD patients were monitored during AECOPD hospitalization and subsequent clinical stability. Serum key pro- and anti-inflammatory molecules were measured. Circulating Th17 and regulatory T (Treg) cells, early-myeloid-derived suppressor cells (e-MDSC), monocytic-MDSC (M-MDSC), and plasmacytoid dendritic cells (pDCs) were analyzed by flow cytometry. Sputum was tested for viruses and bacteria. Eosinophilic inflammation was defined by a blood eosinophil count of ≥ 2%.
resultsThe study included 78 COPD patients and 17 controls. 49% of patients consistently had a non-eosinophilic (Non-Eos) phenotype, and 18% an eosinophilic (Eos) phenotype across both AECOPD and SCOPD. Interestingly, 28% of patients exhibited Non-Eos-AECOPD followed by eosinophilia in SCOPD, while 5% showed the opposite. Immunosuppressive cell frequency increased in both Eos-AECOPD and Non-Eos-AECOPD. While Tregs increases were comparable, the M-MDSC increase in Non-Eos-AECOPD was 1.6 times greater than in Eos-AECOPD. During the stable phase, the Eos phenotype associated with more Tregs and fewer M-MDSCs. Cytokine levels rose significantly during Non-Eos-AECOPD but not in Eos-AECOPD. Critically, within the Non-Eos-AECOPD group, those who later developed eosinophilia in SCOPD showed the most pronounced increases in M-MDSC frequency and cytokine levels.
conclusionsImmunosuppressive cell distribution in SCOPD and triggered immunosuppression pathways during AECOPD are dependent on the inflammatory profile. Understanding the COPD inflammatory phenotype might help predict immune responses and lead to more targeted treatments.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.